Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis

Results: In patients with DM, anti–Mi-2, anti–155/140, andanti–CADM-140weredetectedin9(2%),25(7%),and 43 (11%), respectively. These DM-specific Abs were mutually exclusive and were detected in none of 34 patients withpolymyositis,326withsystemicsclerosis,and97with systemic lupus erythematosus. Anti–Mi-2 was associated with classical DM without interstitial lung disease or malignancy, whereas anti–155/140 was associated with malignancy. Patients with anti–CADM-140 frequently had clinically amyopathic DM and rapidly progressive interstitial lung disease. Cumulative survival rates were more favorable in patients with anti–Mi-2 compared with those with anti–155/140 or anti–CADM-140 (P.01 for both comparisons).Nearlyalldeathsoccurredwithin1yearafter diagnosis in patients with anti–CADM-140. Conclusion:Dermatomyositis-specific Abs define clinically distinct subsets and are useful for predicting clinical outcomes in patients with DM. Arch Dermatol. 2011;147(4):391-398